For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Allogeneic stem cell transplantation followed by targeted immune therapy with Gemtuzumab Ozogamicin (Mylotarg) will be given to patients with average risk AML or MDS.
Wed, 11/02/2011 to Fri, 12/01/2017
Bone Marrow Disease(s):
myelodysplastic syndromes (MDS)
Drug: Gemtuzumab Ozogamicin Gemtuzumab, 9.0 mg/m2, will be given IV over 2 hours two times post allogeneic transplantation. Other Name: Mylotarg